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Abstract 
Introduction 
Dentists prescribe a significant proportion of all antibiotics, while antimicrobial stewardship 
aims to minimise antibiotic-prescribing to reduce the risk of developing antibiotic-resistance 
and adverse drug reactions. 
Aims 
To evaluate NHS antibiotic-prescribing practices of dentists in England between 2010-2017. 
Methods  
NHS Digital 2010-2017 data for England were analysed to quantify dental and general primary-
care oral antibiotic prescribing. 
Results 
Dental prescribing accounted for 10.8% of all oral antibiotic prescribing, 18.4% of amoxicillin 
and 57.0% of metronidazole prescribing in primary care. Amoxicillin accounted for 64.8% of 
all oral antibiotic prescribing by dentists, followed by metronidazole (28.0%), erythromycin 
(4.4%), phenoxymethylpenicillin (0.9%), clindamycin (0.6%), co-amoxiclav (0.5%), 
cephalosporins (0.4%) and tetracyclines (0.3%). Prescriptions by dentists declined during the 
study period for all antibiotics except for co-amoxiclav. This increase is of concern given the 
need to restrict co-amoxiclav use to infections where there is no alternative. Dental prescribing 
of clindamycin, which accounted for 43.9% of primary care prescribing in 2010, accounted for 
only 14.6% in 2017. Overall oral antibiotic prescribing by dentists fell 24.4% as compared to 
14.8% in all of primary care. 
Conclusions  
These data suggest dentists have reduced antibiotic prescribing, possibly more than in other 
areas of primary-care. None-the-less, opportunities remain for further reduction. 
Abstract word count: 200/200 words 
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Introduction 
Antibiotics play an invaluable role in both the treatment and prevention of life-threatening 
infections. An inability to treat infections, however, is the price we may pay if more antibiotics 
become ineffective due to antimicrobial resistant bacteria. Prescribing guidelines and 
antimicrobial stewardship initiatives highlight the need to minimise unnecessary prescribing of 
antibiotics and to ensure that antibiotics are prescribed at the right dose, for the right duration 
and with the optimal spectrum of antimicrobial activity to kill pathogens, while minimising the 
risk of encouraging bacterial drug resistance.1 Since dental oral antibiotic prescribing accounts 
for a significant proportion of all antibiotic prescribing, it is important to monitor dental oral 
antibiotic prescribing trends and to evaluate them in the context of changes in the overall 
prescribing of oral antibiotics in primary care. 
The aim of this study was to evaluate NHS oral antibiotic prescribing practices of dentists in 
England during the period 2010-2017.  
Methods 
Prescription Cost Analysis data held by NHS Digital (https://digital.nhs.uk/data-and-
information/publications/statistical/prescription-cost-analysis) was abstracted to obtain all oral 
antibiotics prescribed in the primary care setting in England between 2010-2017. Prescriptions 
were submitted by physicians, nurse practitioners, and other health care providers, including 
dentists. A further abstraction was performed that restricted the data to oral antibiotics 
prescribed by dentists working in NHS primary care. Hospital and private prescribing of 
antibiotics was not covered.  
These data also provide the net ingredient cost (NIC) for all prescriptions. This is the basic cost 
of a drug used in primary care. This is the list price cost excluding value added tax (VAT), i.e. 
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the price listed in the national Drug Tariff or in standard price lists, but it is not necessarily the 
price the NHS paid. It does not include contract prices or discounts, dispensing costs, fees or 
prescription charge income, so the amount the NHS paid will be different. None-the-less, it 
provides an estimate of the comparative cost of prescribing different medicines and is widely 
used to estimate and compare prescribing costs. 
Based on the relatively small number of prescriptions for individual cephalosporins or 
tetracyclines, all cephalosporin and tetracycline prescriptions were respectively grouped. 
Aminoglycosides were excluded since their oral absorption is minimal to none and they 
accounted for only 0.002% of overall oral antibiotic prescribing and zero dental prescribing. 
Similarly, fosfomycin was not included due to its limited use. Linezolid and tidezolid were not 
included in the analysis since these agents are only prescribed by secondary care. 
Fluoroquinolone data were included in the overall analysis of oral antibiotic use, although there 
was no dental prescribing of fluoroquinolones. Further details regarding oral fluoroquinolone 
use were the focus of a prior publication.2  Oral antibiotics (isoniazid, rifampin, ethambutol, 
para-aminosalicylic acid, pyrazinamide, clofazimine, bedaquiline, rifabutin, rifapentine, 
dapsone, ethionamide, cycloserine, prothionamide, and delamanid) used primarily to treat 
mycobacterial infections were also excluded. 
The numbers of active dentists, patients treated, and courses of dental treatment provided in 
England annually were obtained from NHS Digital, Dental Statistics https://digital.nhs.uk/data-
and-information/publications/statistical/nhs-dental-statistics. The number of practicing dentists 
included those working wholly within the NHS and those working privately, but with some 
NHS activity. NHS digital recorded the number of adult patients treated by counting the number 
seen at least once in the last 24 months, while for children it counted the number seen in the 
last 12 months. These figures were produced quarterly. To estimate the number of patients who 
had dental treatment during each year of the study, June figures for each year were examined. 
6 
The number of adults was halved to obtain an estimate of the number of adults who underwent 
treatment in the preceding 12 months and added this to the figure for children seen in the 
previous 12 months. The number of active general medical practitioners was obtained from the 
British Medical Association. 
https://www.bma.org.uk/-/media/files/pdfs/.../press%20briefings/general-practice.pdf 
Data on other prescriber numbers e.g. nurse practitioners, were not available. It was assumed, 
therefore, that all non-dental primary care prescribing of antibiotics was by general medical 
practitioners, or done under their authority. 
The size of the English population between 2010-2017 (mean 54,137,125) was obtained from 
the Office for National Statistics 
https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration.  
Because all data reported herein were obtained from national data resources and completely 
anonymized, ethics approval was not required. 
Results 
Dental Oral Antibiotic Prescribing Trends 
Between 2010 and 2017, there were 266,652,987 NHS prescriptions for oral antibiotics issued 
in the primary care setting in England by physicians, nurse practitioners, and other health care 
providers, including dentists, at a cost of £1,065,982,500. On average, this amounted to 
33,331,623 prescriptions (616 prescriptions per thousand of the English population) each year 
at an annual cost of £133,247,813. Of these, dentists issued 28,825,698 prescriptions (Table 1), 
10.8% of the total, at a cost of £49,708,614 between 2010-2017. On average, this amounted to 
3,603,212 prescriptions (67 prescriptions per thousand of the English population) at £6,213,577 
per annum (pa) over that period. 
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The mean number of actively practicing dentists in England between 2010-2017 was 23,624 
(Table 2) and each dentist issued, on average, 153 antibiotic prescriptions each year at a mean 
annual cost of £264. This compares to 41,985 general medical practitioners who, on average, 
issued 794 antibiotic prescriptions per year at a mean annual cost of £3,174. Between 2010-
2017, 147.7 million patients received 316.5 million courses of dental treatment (Table 2). On 
average, therefore, one antibiotic prescription was issued for every 5.1 patients treated or for 
every 11 courses of dental treatment. 
Between 2010-2017, dentists issued 18,667,126 amoxicillin prescriptions (Table 1) (mean 
2,333,391 pa), accounting for 64.8% of all antibiotics prescribed by dentists and 18.4% of all 
primary care amoxicillin prescriptions (Table 3). As a class, 19,070,587 penicillin prescriptions 
were issued (mean 2,383,823 pa), accounting for 66.1% of dental antibiotic prescriptions and 
11.2% of all primary care penicillin prescriptions. Metronidazole was the next most frequently 
prescribed antibiotic (8,082,568; mean 1,010,321 pa), accounting for 28.0% of all dental 
antibiotic prescribing (Table 1) but more than half (57%) of all metronidazole prescribing in 
primary care (Table 3). For comparison, all other primary care prescribing of metronidazole, 
i.e. prescribing by doctors, nurse practitioners etc. but not by dentists, amounted to just
6,086,852 prescriptions between 2010-2017 (mean 760,857 pa). The next most frequently 
prescribed dental antibiotics were macrolides (1,301,900; mean 162,737 pa; 4.5% of dental 
antibiotics), of which erythromycin accounted for the vast majority (96.5%), clindamycin 
(167,426; mean 20,928 pa; 0.6% of dental antibiotics), cephalosporins (121,234; 15,154 pa; 
0.4% of dental antibiotics) and tetracyclines (81,983; 10,248 pa; 0.3% of dental antibiotics). 
Dental prescribing of oral antibiotics peaked at 3,935,698 prescriptions pa in 2011 (Table 1, 
Figure 1) and then fell year on year to 2,977,430 in 2017 (a 24.4% fall). Among the penicillins 
(Figure 2), amoxicillin prescribing followed a similar trend, peaking in 2011 and then falling 
22.5% between 2011 and 2017. In contrast, ampicillin prescribing fell to zero in 2014 and 
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ceased thereafter while phenoxymethylpenicillin prescribing progressively fell from 61,675 
prescriptions pa in 2010 to just 12,837 in 2017 (a 79.1% fall). Prescribing of the combined 
agent co-amoxiclav (containing amoxicillin and the beta-lactamase inhibitor clavulanic acid), 
however, increased rapidly between 2010 and 2014 by 130%, from 8,540 prescriptions in 2010 
to 19,620 in 2014. Following this, there was a smaller (20.6%) year on year fall to 15,578 
prescriptions pa in 2017 for this drug. Finally, there was no flucloxacillin prescribing by 
dentists. 
Cephalosporin prescribing fell steadily from 23,478 prescriptions in 2010 to 6,220 in 2017 
(Table 1, Figure 1), with a decline of 73.5%. Tetracycline prescribing also decreased steadily 
from 14,563 prescriptions in 2010 to 6,016 in 2017, representing a 58.7% fall.  
Overall, there was a decline in macrolide prescribing between 2010 and 2017 (Table 1, Figure 
1) which was primarily due to a progressive decline in erythromycin prescribing from 184,311 
prescriptions in 2010 to 107,047 in 2017 (Table 1, Figure 3), a 41.9% fall. This was offset to 
some degree by a rapid increase in prescribing of both azithromycin and clarithromycin (Table 
1, Figure 3). Azithromycin prescribing increased from 301 prescriptions in 2010 to 2,236 in 
2017, which was a 643% increase. Moreover, clarithromycin prescribing increased from 199 
prescriptions in 2010 to 7,654 in 2017, which was a 3746% increase. 
There was a progressive decline (54.6%) in clindamycin prescribing from 31,364 prescriptions 
in 2010 to 14,253 in 2017 (Table 1, Figure 1). Metronidazole prescribing peaked in 2012 at 
1,096,742 prescriptions before falling by 22.8% to 846,207 in 2017 (Table 1, Figure 1). 
Amoxicillin was the most frequently prescribed antibiotic accounting for 64.8% of all antibiotic 
prescriptions by dentists (Figure 4). This was followed by metronidazole (28.0%), 
erythromycin (4.4%), phenoxymethylpenicillin (0.9%), clindamycin (0.6%), co-amoxiclav 
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(0.5%), cephalosporins (0.4%) and tetracyclines (0.3%). All other oral antibiotics combined 
accounted for only 0.1% of all dental prescribing. 
Dental Prescribing Compared To Overall Primary Care Prescribing 
The steady decline in clindamycin prescribing by dentists occurred while primary care 
prescribing of clindamycin overall increased (37%) from 71,395 prescriptions in 2010 to 97,905 
in 2017. Dental prescribing of clindamycin, however, as a percentage of overall clindamycin 
prescribing, fell from 43.9% in 2010 to 14.6% in 2017 (Figure 5). Trends in dental prescribing 
of other antibiotics largely paralleled those in primary care as a whole. Although overall 
antibiotic prescribing by dentists fell slightly more quickly. Thus, overall primary care oral 
antibiotic prescribing accounted for by dentists fell from 11.2% in 2010 to 10% in 2017 (Figure 
5). 
Discussion 
Dental antibiotic prescribing accounts for a sizable (10.8%) proportion of all NHS oral 
antibiotic prescribing in primary care in England. This proportion has increased slightly from 
the 9-10% recorded in WKH¶V.3, 4 However, it is higher than the 8.2% figure in 2017 that 
was recently cited by the report of the English Surveillance Programme for Antimicrobial 
Utilisation and Resistance (ESPAUR).5 This figure is also higher than the 3% of all antibiotic 
prescribing reported for dentists in Australia,6 but lower than 11.8% and 13.2%, respectively, 
that have been reported for Canada7 and the USA.8 
Within dentistry, antibiotics are used for two general purposes, either to treat dental infections 
or prophylactically to prevent infections. During the period covered by our study (2010-2017) 
however, there were no UK guidelines recommending the prophylactic use of antibiotics within 
dentistry. NICE clinical guideline 64 recommending against the use of antibiotic prophylaxis 
to prevent infective endocarditis came into effect in 2008 and by January 2010, antibiotic 
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prophylaxis prescribing in the UK had dropped dramatically.9, 10 The Scottish Dental Clinical 
Effectiveness Program implementation advice recommending that antibiotic prophylaxis 
should be considered for certain individuals e.g. those with prosthetic and repaired heart valves, 
previous history of infective endocarditis and certain congenital heart conditions, did not come 
into effect until August 2018.11 This means that during the period of the study, all antibiotic 
prescribing should have been for treatment of dental infections although a low level of antibiotic 
prophylaxis prescribing by dentists did occur during this period.9 In contrast, dental prescribing 
in other countries during this period included prescribing of antibiotic prophylaxis for those at 
high-risk of infective endocarditis and, in the case of the US, for many patients with prosthetic 
joints. 
Over the period of the study (2010-2017), after peaking in 2012, there was a 14.8% fall in 
overall antibiotic prescribing in primary care,12 possibly reflecting, in part, antimicrobial 
stewardship efforts. After peaking in 2011, the fall in dental antibiotic prescribing was even 
greater (24.4%), despite an upward trend in the number of dentists (Table 2). These figures are 
closely similar to those recently reported in the 2018 ESPAUR report.5 They reported a 13.2% 
fall in antibiotic prescribing in primary care between 2012 and 2017 and a 24.8% fall in dental 
antibiotic prescribing between 2013-2017. This decline could suggest that dentists have 
responded positively to the antimicrobial stewardship message to reduce unnecessary antibiotic 
prescribing to avoid development of antibiotic resistant organisms or it could be due to other 
factors, or a combination of factors. The fall was the result of declines in prescribing of 7 of the 
8 most commonly prescribed antibiotics by dentists as follows, respectively: 1) amoxicillin 
(22.5%), 2) metronidazole (22.8%), 3) erythromycin (41.9%), 4) phenoxymethylpenicillin 
(79.1%), 5) clindamycin (54.6%), 6) cephalosporins (73.5%) and 7) tetracyclines (58.7%). The 
exception was co-amoxiclav; prescribing increased 82.4% between 2010 and 2017. It is 
possible, although not confirmed, that the decline in clindamycin prescribing could have been 
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a response to antimicrobial stewardship messages highlighting the potential of clindamycin to 
cause Clostridioides [previously known as Clostridium] difficile infections that can be 
complicated by recurrent infection and/or life-threatening complications.13-16 
In 2010, dental prescribing of clindamycin accounted for 43.9% of all oral clindamycin 
prescriptions in primary care but by 2017, this had fallen to just 14.6% (Table 3). This 
dramatic fall is explained by the fact that dental clindamycin prescribing fell over this period 
while it was increasing in primary care as a whole. If an antimicrobial stewardship program 
resulted in the decline in clindamycin use, then  this suggests the message may have been 
better responded to by dentists than by GPs. None-the-less, clindamycin remained the 5th most 
frequently prescribed dental antibiotic and warrants additional stewardship attention as recent 
publications have highlight the high adverse reaction risks associated with clindamycin use 
including the risk of C. difficile infection with its associated complications, including death. 
These risks are unparalleled among the antibiotics prescribed by dentists.13, 17, 18 The low and 
falling level of clindamycin prescribing by dentists in the UK contrasts greatly with that in the 
US where clindamycin is the main alternative to amoxicillin, is the second most frequently 
prescribed dental antibiotic and accounts for 15% of all dental antibiotic prescriptions.8  
Although amoxicillin and phenoxymethylpenicillin prescribing have fallen, this was, to some 
extent, compensated for by a rapid 130% rise in co-amoxiclav prescribing between 2010 and 
2014 and a further 21% increase between 2014 and 2017. Co-amoxiclav is a broad-spectrum 
antibiotic with activity against beta-lactamase producing bacteria and therefore plays an 
important role in most hospital formularies for treating antibiotic-resistant and life-threatening 
infections. The large increase in its use in primary-care, without microbiological sensitivity 
testing, is therefore very concerning since its use should be reserved for situations where 
amoxicillin or phenoxymethylpenicillin +/- metronidazole are ineffective. There are several 
potential reasons for the increasing popularity of co-amoxiclav. These include an increased 
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prevalence of beta-lactamase producing bacteria isolated from the mouth,19-21 the effectiveness 
of co-amoxiclav in treating acute dentoalveolar infections,19, 22, 23 and the convenient twice daily 
dosing regimen of co-amoxiclav compared to the three times daily regimen for amoxicillin and 
four times daily regimen for phenoxymethylpenicillin. However, amoxicillin and 
phenoxymethylpenicillin +/- metronidazole remain highly effective in treating acute 
dentoalveolar infections and co-amoxiclav should be reserved for infections where other 
penicillins, particularly amoxicillin, lack efficacy due to the presence of beta-lactamase 
producing bacteria. Moreover, co-amoxiclav may have a significantly worse adverse event 
profile than does amoxicillin alone.13 
In dental abscesses and dentoalveolar infections related to the periodontium e.g. pericoronitis, 
lateral periodontal abscess and acute necrotizing ulcerative gingivitis (ANUG), strictly 
anaerobic Gram-positive cocci and Gram-negative bacilli predominate,24-27 and are 
pathogenic.28 This, and metronidazole¶V activity against anaerobes, make it a good choice for 
treating dental infections,24, 26, 29-34 particularly when patients are warned about the likelihood 
of unpleasant side effects if taken with alcohol. This probably accounts, in part, for the 
relatively small reduction in metronidazole use over the study period. Interestingly, although 
metronidazole is the 2nd antibiotic of choice for dentists in the UK,35 much of Europe,36 Africa,37 
Middle East,38 Indian Subcontinent39, 40 and Australasia,6, 41 in the USA clindamycin is the 
second most-prescribed antibiotic and metronidazole does not appear among the 7 most 
frequently prescribed antibiotics by dentists.8 
Although prescribing of erythromycin, the third most common antibiotic prescribed by dentists 
in England, fell by nearly 42%, this was to some extent compensated for by increased 
prescribing of two other azalide/macrolides, azithromycin and clarithromycin. There was a 
large increase in both of these over the period of study (respectively a 643% and 3746% 
increase) no doubt reflecting their significant advantages over erythromycin as an alternative 
13 
 
to amoxicillin for patients allergic to penicillins. Erythromycin requires four times daily dosage 
and often causes nausea, vomiting and diarrhoea. In comparison, azithromycin and 
clarithromycin exhibit better tissue penetration and efficacy,42, 43 particularly in periodontal 
tissues,44 and require only once daily and twice daily dosing, respectively.  
While antibiotic prescribing in dentistry has fallen, there is still scope for further reductions and 
a more optimal use of antibiotics within dentistry. For example, a recent study of Welsh dental 
antibiotic prescribing found that only 19% of antibiotics were prescribed in situations where 
their use was indicated by clinical guidelines45 including those published in the British National 
Formulary,46 by the Scottish Dental Clinical Effectiveness Programme47 and the Faculty of 
General Dental Practice.48 These guidelines highlight that antibiotics should not be prescribed 
for unexplained pyrexia, cervical lymphadenopathy or facial swelling. In addition, samples 
should be obtained for bacterial culture, particularly for severe infections, where laboratory 
support is available.  The guidelines also emphasize that antibiotics should only be prescribed 
for treatment of identifiable oral infections e.g. acute periapical or periodontal abscess, 
cellulitis, severe pericoronitis, localised osteitis, acute necrotising gingivitis and destructive 
forms of periodontal disease. Moreover, most of these infections should be managed in the first 
instance with early drainage and/or removal of the nidus of infection (e.g. a necrotic pulp) rather 
than with antibiotics alone. They also point out that antibiotics are more appropriately used 
where there is evidence that infection is spreading, and may be required if surgical treatment 
has to be delayed in immunocompromised patients or those with conditions such as diabetes 
mellitus RU3DJHW¶VGLVHDVH&HUWDLQUDUHULQIHFWLRQV, such as bacterial sialadenitis, osteomyelitis, 
DFWLQRP\FRVLV DQG /XGZLJ¶V DQJLQD, however, should prompt urgent specialist care and 
possibly parenteral antibiotic treatment.  
Failure of a patient with infection to respond within 48 hours of surgical drainage and antibiotic 
initiation, should prompt reconsideration of the appropriateness of the antibiotic regimen with 
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any change being based on bacterial culture and antibiotic susceptibility testing results. It is 
notable, that the Welsh study found that 65.5% of antibiotics were prescribed by dentists in the 
absence of evidence of spreading infection, and 70.6% without operative intervention.45  
Other studies support these observations and suggest that factors, such as GHQWLVW¶V concern 
about their ability to perform surgical procedures or to obtain local anaesthesia in the presence 
of infection plus the pressure of balancing the demands of a busy routine patient list with the 
addition of un-scheduled emergency patients, often pressures dentists into prescribing 
antibiotics against guidance or best practice.49-51 
Limitations 
 Although the NHS Digital Prescription Cost Analysis data that were analyzed included the 
number of prescriptions issued in NHS primary dental care in England, it did not provide 
information on the reason the antibiotic was prescribed or on the appropriateness or 
effectiveness of the prescription. Nor did it provide information on the dose or duration of the 
course of antibiotic prescribed. This is important since the inappropriate prescribing of an 
antibiotic, or the prescribing of an antibiotic at too low a dose or for too long, are among the 
most important factors responsible for the selection of antibiotic resistant bacteria.1 Further 
studies are needed to better understand how much of the decline in dental antibiotic prescribing 
that we observed was related to antimicrobial stewardship efforts and/or other factors. Our data 
also did not cover hospital, i.e. secondary care, or private primary-care prescriptions for 
antibiotics for which no centrally recorded data are available. We are unable, therefore, to 
quantify the impact of private prescribing by doctors or dentists on primary care prescribing of 
antibiotics in England. 
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Conclusions 
This study dramatically highlights a number of significant changes in prescribing of oral 
antibiotics by dentists between 2010 and 2017. Likely as a result of antimicrobial stewardship 
messages, there were significant reductions in prescribing of the five antibiotics most frequently 
prescribed by dentists. Most notably, dental prescribing of clindamycin, which has a poor 
adverse drug reaction profile, including C. difficile infection, fell, while prescribing of 
clindamycin increased in the remainder of primary care. These results support the notion that 
dentist have complied with the antimicrobial stewardship message and antibiotic prescribing 
guidelines, with a steady downward progression in the prescribing of most commonly 
prescribed oral antibiotics. None-the-less, further progress can be made, and Public Health 
England have produced a Dental Antimicrobial Stewardship Toolkit to help primary care 
practitioners promote the appropriate use of antibiotics in dentistry. This is available at: 
https://www.gov.uk/guidance/dental-antimicrobial-stewardship-toolkit#the-toolkit  
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Figure legends: 
Figure 1. 
Antibiotic prescribing by dentists (by antibiotic class) 
 
Figure 2.  
 
Penicillin prescribing by dentists 
Figure 3.  
Macrolide prescribing by dentists 
Figure 4.  
 
The proportion of all dental antibiotic prescribing represented by different individual antibiotics 
Figure 5.  
 
Dental antibiotic prescribing as a percentage of all primary care prescribing of oral antibiotics
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Table 1. Number of oral antibiotics prescribed by dentists 
Drug Name 2010 2011 2012 2013 2014 2015 2016 2017 2010-17 
Amoxicillin 2,466,648 2,527,700 2,523,921 2,458,078 2,396,085 2,238,981 2,096,367 1,959,346 18,667,126
Ampicillin 198 184 121 42 0 0 0 0 545
Co-Amoxiclave 8,540 15,161 18,426 18,758 19,620 18,630 17,421 15,578 132,134
Flucloxacillin 0 0 0 0 0 0 0 0 0
Phenoxymethylpenicillin 61,675 52,708 43,224 35,011 27,406 21,331 16,554 12,873 270,782
All Penicillins 2,537,061 2,595,753 2,585,692 2,511,889 2,443,111 2,278,942 2,130,342 1,987,797 19,070,587
Cephalosporins 23,478 22,579 19,665 15,735 14,109 11,202 8,246 6,220 121,234
Tetracyclines 14,563 13,773 12,497 10,670 9,129 8,030 7,305 6,016 81,983
Azithromycin 301 450 1,206 1,716 2,142 2,253 2,199 2,236 12,503
Clarithromycin 199 1,511 3,382 4,088 4,781 5,506 6,398 7,654 33,519
Erythromycin 184,311 185,246 181,095 171,872 159,539 142,235 124,533 107,047 1,255,878
All Macrolides 184,811 187,207 185,683 177,676 166,462 149,994 133,130 116,937 1,301,900
Clindamycin 31,364 26,939 24,118 20,415 18,360 16,524 15,453 14,253 167,426
Metronidazole 1,059,496 1,089,447 1,096,742 1,068,871 1,044,848 972,869 904,088 846,207 8,082,568
All Oral Antibiotics 3,850,773 3,935,698 3,924,397 3,805,256 3,696,019 3,437,561 3,198,564 2,977,430 28,825,698
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Table 2. Number of dentists, patients and courses of treatment 
 2010 2011 2012 2013 2014 2015 2016 2017 Mean Total 
Dentists 22,799 22,920 23,201 23,723 23,947 24,089 24,007 24,308 23,624  188,994 
Patients (million) 18.116 18.474  18.696  18.834  18.914  19.010  17.796  17.880  18.465 147.720 
Courses of Treatment (million) 39.245 39.751 39.322  39.762  39.612  39.683  39.925  39.213  39.564  316.513 
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Table 3. Dental prescribing of oral antibiotics as a % of all oral antibiotic prescribing 
 
Drug Name 2010 2011 2012 2013 2014 2015 2016 2017 2010-17 
Amoxicillin 18.3 18.9 17.5 18.6 18.5 18.9 18.0 18.2 18.4 
Ampicillin 2.0 2.6 2.2 1.0 0.0 0.0 0.0 0.0 1.5 
Co-Amoxiclave 0.4 0.7 0.8 0.8 0.9 1.0 1.1 1.0 0.8 
Flucloxacillin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Phenoxymethylpenicillin 2.4 2.1 1.7 1.4 1.1 0.9 0.7 0.6 1.4 
All Penicillins 11.4 11.7 11.0 11.3 11.1 11.2 10.8 10.7 11.2 
Cephalosporins 1.1 1.3 1.3 1.2 1.1 1.1 0.9 0.7 1.1 
Tetracyclines 0.4 0.4 0.3 0.3 0.2 0.2 0.2 0.1 0.3 
Azithromycin 0.1 0.1 0.3 0.4 0.4 0.4 0.3 0.3 0.3 
Clarithromycin 0.0 0.1 0.1 0.2 0.2 0.2 0.3 0.3 0.2 
Erythromycin 6.7 7.2 7.1 7.9 8.1 8.9 9.2 9.6 7.8 
All Macrolides 4.1 4.0 3.6 3.6 3.4 3.3 3.0 2.8 3.5 
Clindamycin 43.9 36.0 30.1 24.8 20.5 18.2 16.3 14.6 24.6 
Metronidazole 56.5 56.8 56.9 57.5 57.5 57.1 57.1 57.0 57.0 
All Oral Antibiotics 11.2 11.5 10.8 11.0 10.8 10.7 10.3 10.0 10.8 
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